References
- Young PA, Gaut D, Kimaiyo DK, et al. Durable survival outcomes in primary and secondary Central nervous system lymphoma after high-dose chemotherapy and autologous stem cell transplantation using a thiotepa, busulfan, and cyclophosphamide conditioning regimen. Clin Lymphoma Myeloma Leuk. 2020;20(7):468–479.
- Ghafouri S, Timmerman J, Larson S, et al. Axicabtagene ciloleucel CAR T-cell therapy for relapsed/refractory secondary CNS non-Hodgkin lymphoma: comparable outcomes and toxicities, but shorter remissions may warrant alternative consolidative strategies? Bone Marrow Transplant. 2021;56(4):974–977.
- Frigault MJ, Maus MV, Dietrich J, et al. Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma. Blood. 2019;134(11):860–866.
- Klyuchnikov E, Bacher U, Kroll T, et al. Allogeneic hematopoietic cell transplantation for diffuse large B cell lymphoma: who, when and how. Bone Marrow Transplant. 2014;49(1):1–7.
- Aldoss I, Al Malki MM, Stiller T, et al. Implications and management of Central nervous system involvement before allogeneic hematopoietic cell transplantation in acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2016;22(3):575–578.
- Varadi G, Or R, Kapelushnik J, et al. Graft-Versus-Lymphoma effect after allogeneic peripheral blood stem cell transplantation for primary Central nervous system lymphoma. Leuk Lymphoma. 1999;34(1-2):185–190.
- Atilla E, Sahin U, Atilla PA, et al. Allogeneic stem cell transplantation for relapsed primary Central nervous system lymphoma: is it feasible? Hematol Oncol Stem Cell Ther. 2019 Dec;12(4):220–225.
- Mika T, Ladigan S, Baraniskin A, et al. Allogeneic hematopoietic stem cell transplantation for primary Central nervous system lymphoma. Haematologica. 2020;105(4):E160–E163.
- Sterling CH, Tsai HL, Holdhoff M, et al. Allogeneic blood or marrow transplantation with nonmyeloablative conditioning and High-Dose Cyclophosphamide-Based graft-versus-Host disease prophylaxis for secondary Central nervous system lymphoma. Transplant Cell Ther. 2021;27(10):863.e1-863–e5.
- Spruit JL, Fagoaga OR, Savaşan S. Donor cell chimerism evaluation in cerebrospinal fluid by short tandem repeat analysis following allogeneic hematopoietic stem cell transplantation. Hum Immunol. 2018;79(7):537–538.
- Abdel-Azim H, Kapoor N, Mahadeo KM, et al. Graft versus tumor effect in the brain of a child with recurrent metastatic medulloblastoma. Pediatr Blood Cancer. 2015;62(9):1667–1669.
- Bacher U, Klyuchnikov E, Le-Rademacher J, Lymphoma Working Committee of the CIBMTR, et al. Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity? Blood. 2012;120(20):4256–4262.
- Scordo M, Wang TP, Ahn KW, et al. Outcomes associated with Thiotepa-Based conditioning in patients with primary Central nervous system lymphoma after autologous hematopoietic cell transplant. JAMA Oncol. 2021;7(7):993–1003.
- Pérez-Simón JA, Díez-Campelo M, Martino R, et al. Influence of the intensity of the conditioning regimen on the characteristics of acute and chronic graft-versus-host disease after allogeneic transplantation. Br J Haematol. 2005;130(3):394–403.
- Urbano-Ispizua A, Pavletic SZ, Flowers ME, et al. The impact of graft versus host disease on relapse rate in patients with lymphoma depends on the histological Sub-type and the intensity of the conditioning regimen. Biol Blood Marrow Transplant. 2015;21(10):1746–1753.
- Zurko J, Ramdial J, Shadman M, et al. Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma. Haematologica. 2022 Jul 14. doi: 10.3324/haematol.2022.281242. Online ahead of print.